FDA's 2026 headline means eligible people with early Alzheimer's can start treatment with weekly Leqembi IQLIK shots at home instead of beginning with IV infusions. Leqembi IQLIK is subcutaneous lecanemab-irmb, an anti-amyloid drug for early Alzheimer's disease. Eisai and Biogen announced that FDA approved the initiation use on July 13, 2026, according to the Eisai approval announcement.
Eisai describes it as the first anti-amyloid treatment worldwide offering at-home dosing for both initiation and maintenance, according to the Eisai U.S. statement. Read the headline as a dosing change, not a new patient group or lower risk.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Apply through Eisai’s official page — Use this page to review requirements and apply directly.
- Read the official guidance from Cision — Use this primary source to verify the official guidance.
Table of Contents
- Who is the starting dose for?
- What does at-home initiation involve?
- What changed since the 2025 approval?
- What safety monitoring still applies?
Who is the starting dose for?
Treatment is for adults with mild cognitive impairment or mild dementia due to Alzheimer's. Those two stages are together called early Alzheimer's.
Amyloid-beta pathology must be confirmed before starting, according to the Federal Employee Program policy citing the FDA label in the July 2026 drug policy. A memory-clinic evaluation usually documents diagnosis, other causes, medicines, and brain-scan history. Use this quick check before calling your clinic:.
- diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's
- test result showing amyloid-beta pathology
- plan for baseline and follow-up MRI scans
- caregiver or home support for weekly injections
What does at-home initiation involve?
The FDA-authorized starting regimen sold as LEQEMBI IQLIK is 500 mg once weekly. It is given as two 250-mg autoinjector injections, each delivered in about 15 seconds, according to the BioArctic approval notice. That routine replaces IV infusions from treatment start.
Home dosing still needs training on storage, injection sites, missed-dose rules, and when to seek care. Ask who prescribes, who teaches the first injections, and how your clinic tracks refills and side effects. Keep a simple weekly log with date, site, and any headache, confusion, dizziness, vision change, or unusual bleeding concern.
What changed since the 2025 approval?
FDA first approved IQLIK 360 mg weekly only as maintenance after 18 months of IV lecanemab. That rule comes from the approval history reported by the Drugs.com Leqembi history. Patients can now begin without prior IV treatment.
Eisai said initiation approval rested on Clarity AD extension substudies showing weekly subcutaneous dosing reached exposure and amyloid clearance comparable to IV dosing. The practical shift is access and setting. Fewer infusion visits may help people far from infusion centers or with difficult veins. Eligibility, amyloid confirmation, and monitoring did not disappear with the needle change.
What safety monitoring still applies?
Lecanemab carries a boxed warning for amyloid-related imaging abnormalities with edema. These events can cause brain swelling, hemorrhage, and death, and they require baseline and scheduled MRI monitoring, as reported in the Drugs.com FDA safety summary. At-home injections do not make MRI scans optional.
Confirm the scan schedule, contrast rules, and after-hours contact before the first dose. Tell the care team promptly about severe headache, confusion, trouble speaking, weakness, vision changes, dizziness, nausea, or a fall with head injury. Bring your medicine list because bleeding risk and other brain conditions affect decisions.
You Might Also Like
- Safety Questions After the 2026 LiBBY Dementia Trial: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
- AAIC 2026 LiBBY THC-CBD Agitation Trial: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
- AAIC 2026 Findings on Retired Elite Soccer Players: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
